Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 20, Issue 9, 2007, Pages 677-685

  Jansson, Lauren M ^a,c   Dipietro, Janet A ^b   Elko, Andrea ^c   Velez, Martha ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Infant; Methadone; Neonatal abstinence syndrome; Vagal tone

Indexed keywords

AMPHETAMINE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; COCAINE; FLUOXETINE; METHADONE; OPIATE; OPIATE DERIVATIVE; PAROXETINE; PSYCHOTROPIC AGENT; SERTRALINE; TETRAHYDROCANNABINOL;

ADULT; ANALYSIS OF VARIANCE; ANAMNESIS; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG USE; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEALTH CARE FACILITIES AND SERVICES; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SEX DIFFERENCE; SINUS ARRHYTHMIA; SUBSTANCE ABUSE; VAGUS TONE; WITHDRAWAL SYNDROME;

ADULT; APGAR SCORE; ARRHYTHMIA, SINUS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; INFANT, NEWBORN; MALE; METHADONE; MOTHERS; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS; TREATMENT OUTCOME; VAGUS NERVE DISEASES;

EID: 34547894243     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050701490327     Document Type: Article

References (48)

1. Finnegan L, Erlich S. Maternal drug abuse during pregnancy: Evaluation and pharmacotherapy for neonatal abstinence. In: Adler MW, Cowan A, editors. Modern Methods in Pharmacological Testing and Evaluation of Drugs of Abuse. New York: Wiley-Liss; 1990. pp 255-263.
2. Davis RC, Chappel JN, Mejia-Zelaya A, Madden J. Clinical observations on methadone-maintained pregnancies. In: Harbison R, editor. Perinatal addiction. New York: Spectrum; 1975. pp 101-112.
3. Malpas TJ, Darlow BA, Lennox R, Horwood LJ. Maternal methadone dosage and neonatal withdrawal. Aust N Z J Obstet Gynaecol 1995;35:175-177.
4. Doberczak TM, Kandall SR, Friedmann P. Relationships between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993;81:936-940.
5. McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dose methadone maintenance in pregnancy: Maternal and neonatal outcomes. Am J Obstet Gynecol 2005;93:606-610.
6. Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003;189:312-317.
7. Mack G, Thomas D, Giles G, Buchanan N. Methadone levels and neonatal withdrawal. J Paediatr Child Health 1991;27:96-100.
8. Dasche JS, Sheffield JS, Olscher DA, Todd SL, Jackson GL, Wendel GD. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002;100:1244-1249.
9. Strauss ME, Andresko M, Stryker JC, Wardell JN. Relationship of neonatal withdrawal to maternal methadone dose. Am J Drug Alcohol Abuse 1976;3:339-345.
10. Madden JD, Chappel JN, Zuspan F, Gumpel J, Mejia A, Davis R. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol 1977;127:199-201.
11. Ostrea EM, Chavez CJ, Strauss ME. A study of factors that influence the severity of neonatal withdrawal. J Pediatr 1976;88:642-645.
12. Nekhayeva IA, NonovskayaTN,Deshmukh SV, Zharikova OL, Hankins GD, Ahmed MS. Bidirectional transfer of methadone across human placenta. BiochemPharmacol 2005;69:187-197.
13. Wolff K, Boys A, Rostami-Hodjegan A, Hays A, Raistrick D. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 2005;61:763-768.
14. Nagy E, Loveland KA, Orvos H, Molnar P. Gender-related physiologic differences in human neonates and the greater vulnerability of males to developmental brain disorders. J Gend Specif Med 2001;4:41-49.
15. Weinberg M, Tronick EZ, Cohn JF, Olson KL. Gender differences in emotional expressivity and self-regulation during early infancy. Dev Psychol 1999;35:175-188.
16. Morse S, Wu SS, Ma C, Ariet M, Resnick M, Roth J. Racial and gender differences in the viability of extremely low birth weight infants: A population-based study. Pediatrics 2006;117:e106-112.
17. Anyaegbunam A, Tran T, Jadali D, Randolph G, MikhailMS. Assessment of fetal well-being in methadone-maintained pregnancies: Abnormal non-stress tests. Gynecol Obstet Invest 1997;43:25-28.
18. Levine A, Rebarber A. Methadone maintenance treatment and the nonstress test. J Perinatol 1995;15:229-231.
19. Archie C, Lee MI, Sokol RJ, Norman G. The effects of methadone treatment on the reactivity of the nonstress test. Obstet Gynecol 1989;74:254-255.
20. Cejtin H, Mills A, Swift E. Effect of methadone on the biophysical profile. J Reprod Med 1996;41:819-822.
21. Wouldes TA, Roberts AB, Pryor JE, Bagnall C, Gunn TR. The effect of methadone treatment on the quantity and quality of human fetal movement. Neurotoxicol Teratol 2004;26:23-34.
22. Jansson L, Elko A, DiPietro J. Fetal response to maternal methadone administration. Am J Obstet Gynecol 2005;193:611-617.
23. Bazhenova O, Plonskaia O, Porges S. Vagal reactivity and affective adjustment in infants during interactive challenges. Child Dev 2001;72:1314-1326.
24. Porges S, Greenspan S. Regulatory disorders. II: Psychophysiologic perspectives. NIDA Res Monogr 1991;114:173-181.
25. Grossman P, van Beek J, Wientjes C. A comparison of three quantification methods for estimation of respiratory sinus arrhythmia. Psychophysiology 1990;27:702-714.
26. Porges S. Vagal tone: A physiologic marker of stress vulnerability. Pediatrics 1992;90:498-504.
27. Porges S. Vagal tone: An autonomic mediator of affect. In: Garber J, Dodge K, editor. The development of emotion, regulation and dysregulation. New York: Cambridge University Press; 1991. pp 111-128.
28. Newlin D, Byrne E, Porges S. Vagal mediation of the effect of alcohol on heart rate. Alcohol Clin Exp Res 1990;14:421-424.
29. Newlin DB, Pretorius MB, Wong CJ, Dax EM. Acute marijuana smoking reduces vagal tone. NIDA Res Monogr 1990;105:565-566.
30. Newlin D. Effect of cocaine on vagal tone: A common factors approach. Drug Alcohol Depend 1995;37:211-216.
31. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 1991;118:933-937.
32. The American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 1998;101:1079-1088.
33. Kreek M. Plasma and urine levels of methadone. NY State J Med 1973;23:2773-2777.
34. Handelsman L, Cochrane KJ, Aronson MJ, Ness RA, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 1987;13:293-308.
35. Lintzeris N, Bammer G, Rushworth L, Jolley DJ, Whelan G. Buprenorphine dosing regime for inpatient heroin withdrawal: A symptom-triggered dose titration study. Drug Alcohol Depend 2003;70:287-294.
36. Finnegan L, Connaughton JF, Kron RE, Emich JP. Neonatal abstinence syndrome: Assessment and management. Addict Dis 1975;2:141-158.
37. Porges S. Respiratory sinus arrhythmia: Physiological basis, quantitative methods, and clinical implications. In: Grossman P, Janssen K, Vaitl D, editors. Cardiorespiratory and cardiosomatic psychophysiology. New York: Plenum; 1986. pp 101-115.
38. Willett J. Measuring change: What individual growth curve modeling buys you. In: Amsel E, Renninger K, editors. Change and development: Issues of theory, method and application. Mahwah, NJ: Lawrence Erlbaum Associates; 1997. pp 213-243.
39. Johnson H, Rosen T. Prenatal methadone exposure: Effects on behavior in early infancy. Pediatr Pharmacol 1982;2:113-120.
40. Rissanen A, Naukkarinen H, Virkkunen M, Rawlings RR, Linnoila M. Fluoxetine normalizes increased cardiac vagal tone in bulemia nervosa. J Clin Psychopharmacol 1998;18:26-32.
41. Tanaka M, Nakahara T, Muranaga T, Kojima S, Yasuhara D, Ueno H, Nakazato M, Inui A. Ghrelin concentrations and cardiac vagal tone are decreased after pharmacologic and cognitive-behavioral treatment in patients with bulimia nervosa. Horm Behav 2006;50:261-265.
42. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-469.
43. Hamilton SP, Nunes EV, Janal M, Weber L. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000;9:63-69.
44. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-176.
45. Beaulac-Baillargeon L, Boucher N. Neonatal adverse reactions after in utero exposure to selective serotonin reuptake inhibitors: Still controversial. Arch Pediatr Adolesc Med 2006;160:855-856.
46. Godding V, Bonnier C, Fiasse L, Michel M, Longueville E, Lebecque P, Robert A, Galanti L. Does in utero exposure to heavy maternal smoking induce nicotine withdrawal symptoms in neonates? Pediatr Res 2004;55:654-651.
47. Bornstein M, Suess P. Child and mother cardiac vagal tone: Continuity, stability and concordance across the first 5 years. Dev Psychol 2000;36:54-65.
48. Finnegan LP, Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman RA, Friedman SB, Nelson NM, Seidel HM, editors. Primary pediatric care. Second ed. St Louis MO: Mosby Year Book; 1992. pp 1367-1378.